Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
Fish and Richardson
Queensland Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 065079

« Back to Dashboard

NDA 065079 describes PENICILLIN G POTASSIUM, which is a drug marketed by Mylan, Purepac Pharm, Apothecon, Consolidated Pharm, Hanford Gc, Istituto Bio Ita Spa, Lilly, Parke Davis, Pfizer, Sandoz, Watson Labs Inc, Ivax Sub Teva Pharms, Teva, Wyeth Ayerst, and Baxter Hlthcare, and is included in twenty NDAs. It is available from three suppliers. Additional details are available on the PENICILLIN G POTASSIUM profile page.

The generic ingredient in PENICILLIN G POTASSIUM is penicillin g potassium. There are eighty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the penicillin g potassium profile page.

Summary for 065079

Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 065079


Suppliers and Packaging for NDA: 065079

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PENICILLIN G POTASSIUM penicillin g potassium INJECTABLE;INJECTION 065079 ANDA Sandoz Inc 0781-6135 0781-6135-95 10 VIAL in 1 CARTON (0781-6135-95) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0781-6135-94)
PENICILLIN G POTASSIUM penicillin g potassium INJECTABLE;INJECTION 065079 ANDA Sandoz Inc 0781-6136 0781-6136-94 1 VIAL in 1 CARTON (0781-6136-94) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Aug 30, 2002TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength5,000,000 UNITS/VIAL
Approval Date:Aug 30, 2002TE:APRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength20,000,000 UNITS/VIAL
Approval Date:Aug 30, 2002TE:APRLD:No

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: